AccessibilityHelpAbout Us
Nxera Pharma logo

Nxera Pharma(OTC) SOLTF

Market Cap$715.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-82%
5 Year-53%
1 Year+13%
1 Month+53%
$7.64
-2.43%
-0.19Today
Nxera Pharma last closing stock price
MetricPriceDate
Last closeUSD 7.642026-09-16
Nxera Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.49%USD 7.842026-09-09
1 month+52.5%USD 5.012026-08-06
3 month+23.52%USD 6.192026-06-05
Year to date+39.42%USD 5.482025-12-29
1 year+12.6%USD 6.792025-09-15
3 year-28.26%USD 10.652023-09-14
5 year-53.21%USD 16.332021-07-15
Since inception-81.9%USD 43.252014-08-29

Nxera Pharma Financials at a Glance

Market Cap

$715.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥33.55B

Net Income (TTM)

-¥7.82B

EPS (TTM)

-$0.58

P/E Ratio

-13.82

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$7.64

Volume

3,000

Open

$7.86

Previous Close

$7.64

Daily Range

$7.64 - $7.86

52-Week Range

$4.90 - $8.06

Estimated Earnings Date

Nov 6, 2026

SOLTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nxera Pharma

Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise focused on developing and commercializing pharmaceutical products globally. The company operates in multiple countries, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom, offering a diverse range of established treatments.

Products and Services
  • Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease
  • Enerzair and Breezhaler for asthma management
  • ORAVI for oropharyngeal candidiasis and PIVLAZ for cerebral vasospasm
Growth Outlook
  • Strong R&D pipeline with investigational compounds for various conditions
  • Strategic alliances with industry leaders like AbbVie and Pfizer enhance market reach
  • Focus on innovative therapies positions Nxera Pharma for future growth
Financial Highlights
  • Recent quarterly revenue of 7.6 billion JPY, showing resilience
  • TTM gross profit margin of 76%, indicating strong product demand
  • Current ratio of 2.66, reflecting solid liquidity position
Nxera Pharma Co., Ltd. is well-positioned in the biotechnology sector, with a robust portfolio of products aimed at addressing significant health challenges. The company's commitment to research and development is evident in its extensive pipeline of investigational compounds targeting various diseases, including immuno-oncology and neuropsychiatric conditions. Strategic partnerships with major pharmaceutical companies further bolster its market presence and enhance its ability to innovate. Recent financial performance indicates resilience, with a notable revenue figure in the latest quarter. The gross profit margin reflects strong demand for its products, while a healthy current ratio suggests a solid liquidity position, allowing for continued investment in growth initiatives. Overall, Nxera Pharma presents a compelling opportunity for investors interested in the biotechnology sector, driven by innovation and strategic partnerships.
AI Generated • Sep 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

382

CEO

Chris Cargill

Website

www.nxera.life

Headquarters

Tokyo, TY 107-0052, JP

SOLTF Financials

Key Financial Metrics (TTM)

Gross Margin

76.05%

Operating Margin

-6.52%

Net Income Margin

-23.34%

Return on Equity

-12.23%

Return on Capital

-6.83%

Return on Assets

-5.89%

Earnings Yield

-7.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$715.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

91.38M

Volume

3.00K

Avg. Volume

57.286

Financials (TTM)

Gross Profit

¥25.51B

Operating Income

-¥2.20B

EBITDA

¥2.78B

Operating Cash Flow

¥779.77M

Capital Expenditure

-¥607.67M

Free Cash Flow

¥172.11M

Cash & ST Invst.

¥17.62B

Total Debt

¥54.01B

Nxera Pharma Performance Analysis

Nxera Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31JPY 118,370,543-26.6%
20232023-12-31JPY 90,788,244-23.3%
20242024-12-31JPY 190,336,436109.6%
20252025-12-31JPY 197,961,8714.0%
Nxera Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-18.9%
Q42025-12-3113.5%
Q12026-03-3145.7%
Q22026-06-30-32.9%
Nxera Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31JPY 0.04-68.8%
20232023-12-31JPY -0.62N/A
20242024-12-31JPY -0.36-42.6%
20252025-12-31JPY -0.93160.7%
Nxera Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3031.7%
Q42025-12-31-379.0%
Q12026-03-31120.4%
Q22026-06-30-112.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

¥7.60B

-10.1%

Gross Profit

¥5.45B

-17.3%

Gross Margin

71.74%

N/A

Market Cap

$715.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.87M

N/A

Employees

382

N/A

Net Income

-¥200.54M

+91.6%

EBITDA

¥229.33M

-56.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

¥17.62B

-46.7%

Total Debt

¥54.01B

-16.5%

Accounts Receivable

¥10.61B

+56.0%

Inventory

¥10.00B

+14.7%

Long Term Debt

¥46.60B

-19.7%

Short Term Debt

¥7.41B

+11.0%

Return on Assets

-5.89%

N/A

Return on Invested Capital

-1.86%

N/A

Free Cash Flow

¥5.54B

+2150.6%

Operating Cash Flow

¥5.59B

+3204.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BPMUFBasilea Pharmaceutica AG
$77.40+0.00%
VBIZFViva Biotech Holdings
$0.19+0.00%
BOVNFBioInvent International AB (publ)
$3.29+0.00%
GSGTFGenSight Biologics S.A.
$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MEDSDataMEDS Ai
$6.07+274.69%
AALAmerican Airlines Group
$12.70-0.55%
NOKNokia
$10.14+3.05%
INTCIntel
$101.05+4.03%

Questions About SOLTF

What is the current price of Nxera Pharma?

Nxera Pharma is trading at $7.64 per share.

What is the 52-week range for Nxera Pharma?

Over the past 52 weeks, Nxera Pharma has traded between $4.90 and $8.06.

How much debt does Nxera Pharma have?

As of the most recent reporting period, Nxera Pharma reported total debt of ¥334.75M.

How much cash does Nxera Pharma have on hand?

Nxera Pharma reported ¥109.20M in cash and cash equivalents in its most recent financial results.

What is Nxera Pharma’s dividend yield?

Nxera Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services